-+ 0.00%
-+ 0.00%
-+ 0.00%
Daiichi Sankyo’s Enhertu plus pertuzumab wins EU approval for first-line HER2+ metastatic breast cancer
Share
Listen to the news
Daiichi Sankyo’s Enhertu plus pertuzumab wins EU approval for first-line HER2+ metastatic breast cancer
  • European Commission cleared Enhertu with pertuzumab for first-line unresectable or metastatic HER2-positive breast cancer.
  • DESTINY-Breast09 showed a 44% lower risk of progression or death versus THP; median PFS 40.7 months versus 26.9 months.
  • AstraZeneca to pay Daiichi Sankyo USD 100 million milestone tied to the EU first-line metastatic indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609010230BIZWIRE_USPR_____20260831_BW763332) on September 01, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending